Denufosol, also known as INS-37217, a P2Y2 agonist potentially for the treatment of cystic fibrosis. Cystic fibrosis is characterised by a defect of the chloride channel CFTR (cystic fibrosis transmembrane conductance regulator) on epithelial cells in the lungs. The CFTR regulates the components of sweat, digestive juices, and mucus. Defects lead to a viscous, dehydrated mucus, hindering mucociliary clearance. Denufosol is an agonist at the P2Y2 subtype of purinergic receptors, an alternative chloride channel. Activating this alternate chloride channel theoretically increases ion transport in cystic fibrosis patients which compensates the effects caused by the non-functioning CFTR.
MedKoo Cat#: 326947
Name: Denufosol tetrasodium
CAS#: 318250-11-2 (sodium)
Chemical Formula: C18H23N5Na4O21P4
Exact Mass:
Molecular Weight: 861.25
Elemental Analysis: C, 25.10; H, 2.69; N, 8.13; Na, 10.68; O, 39.01; P, 14.39
The following data is based on the product molecular weight 861.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
